Company Presentation

Oculis Operations Sarl

Category:Clinical Stage Biotech Company
Time:15:30 – 15:45
Speaker:Bastian Dehmel, Chief Development Officer

Company profile

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline includes: OCS-01, a topical candidate in Phase 3 for diabetic macular edema ; OCS-02, a topical biologic candidate in Phase 2b for dry eye disease ; and OCS-05, a disease modifying candidate for acute optic neuritis. Oculis’ goal is to deliver life-changing eye treatments to patients worldwide.

Follow us